Lixte Biotechnology Holdings Inc (LIXT)
2.71
-0.08
(-2.87%)
USD |
NASDAQ |
May 08, 16:00
2.71
0.00 (0.00%)
After-Hours: 20:00
Lixte Biotechnology Holdings Cash from Financing (TTM): 3.143M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 3.143M |
September 30, 2023 | 3.143M |
June 30, 2023 | 0.0063M |
March 31, 2023 | 5.159M |
December 31, 2022 | 5.141M |
September 30, 2022 | 5.151M |
June 30, 2022 | 5.241M |
March 31, 2022 | 0.1901M |
December 31, 2021 | 3.897M |
September 30, 2021 | 8.620M |
June 30, 2021 | 8.455M |
March 31, 2021 | 8.298M |
December 31, 2020 | 4.602M |
September 30, 2020 | -0.1302M |
June 30, 2020 | -0.0559M |
March 31, 2020 | 0.00 |
December 31, 2019 | |
September 30, 2019 | |
June 30, 2019 | |
March 31, 2019 | |
December 31, 2018 | |
September 30, 2018 | |
June 30, 2018 | |
March 31, 2018 | |
December 31, 2017 | 2.518M |
Date | Value |
---|---|
September 30, 2017 | 2.518M |
June 30, 2017 | 2.50M |
March 31, 2017 | 1.581M |
December 31, 2016 | 1.748M |
September 30, 2016 | 1.748M |
June 30, 2016 | 1.748M |
March 31, 2016 | 1.482M |
December 31, 2015 | 2.052M |
September 30, 2015 | 2.052M |
June 30, 2015 | 2.052M |
March 31, 2015 | 3.150M |
December 31, 2014 | 1.412M |
September 30, 2014 | 1.412M |
June 30, 2014 | 1.412M |
March 31, 2014 | 0.00 |
December 31, 2013 | 0.00 |
September 30, 2013 | 0.00 |
June 30, 2013 | 0.00 |
March 31, 2013 | 2.468M |
December 31, 2012 | 2.502M |
September 30, 2012 | 2.502M |
June 30, 2012 | 2.502M |
March 31, 2012 | 0.0383M |
December 31, 2011 | 0.005M |
September 30, 2011 | 0.005M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-0.1302M
Minimum
Sep 2020
8.620M
Maximum
Sep 2021
3.804M
Average
4.250M
Median
Cash from Financing (TTM) Benchmarks
iBio Inc | 10.68M |
PAVmed Inc | 31.17M |
PDS Biotechnology Corp | 16.38M |
Moleculin Biotech Inc | 4.651M |
Syros Pharmaceuticals Inc | 43.46M |